Similar articles

• Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections.

  Flannery B, Schrag S, Bennett NM, Lynfield R, Harrison LH, Reingold A, Cieslak PR, Hadler J, Farley MM, Facklam RR, Zell ER, Whitney CG; Active Bacterial Core Surveillance/Emerging Infections Program Network. Flannery B, et al. JAMA. 2004 May 12;291(18):2197-203. doi: 10.1001/jama.291.18.2197. JAMA. 2004. PMID: 15138241
• [Advice of the French Superior Council on Public Health (section on transmissible diseases) relative to vaccination by heptavalent pneumococcal conjugate vaccine (Prevanar). Meeting of March 8, 2002].

  [No authors listed] [No authors listed] Arch Pediatr. 2002 Aug;9(8):862-4. Arch Pediatr. 2002. PMID: 12212580 French.
• From the Centers for Disease Control and Prevention. Decreased availability of pneumococcal conjugate vaccine.

  [No authors listed] [No authors listed] JAMA. 2001 Nov 14;286(18):2232. JAMA. 2001. PMID: 11757530 No abstract available.
• A conjugate vaccine for the prevention of pediatric pneumococcal disease.

  Murray D, Jackson C. Murray D, et al. Mil Med. 2002 Aug;167(8):671-7. Mil Med. 2002. PMID: 12188240 Review.
• The heptavalent conjugate pneumococcal vaccine and its implications for managed care--clinical overview and roundtable discussions.

  Alexander PG, Chartrand SA, Davies TJ, Gaines BM, Oster G, Shurin P, Tamsky L, Thornton DK, Wittert W. Alexander PG, et al. Manag Care Interface. 2001;Suppl C:10-28; quiz 29-30. Manag Care Interface. 2001. PMID: 11724029 Review. No abstract available.